Mass General Brigham shared a post on LinkedIn:
“The next phase of blood cancer treatment will be defined by new therapies and how quickly they reach patients, through earlier treatment, off-the-shelf formats and wider access.
In a recent webinar convened by Bank of America Global Research, featuring KOLs from Mass General Brigham and Harvard, Noopur Raje MD and Jeremy Abramson MD examined the science and clinical developments reshaping the treatment of myeloma and lymphoma.
The conversation spanned bispecific antibodies, CAR T-cell therapy, off-the-shelf approaches, sequencing and the community access gap that decides who benefits.
Read the full discussion.
The conversation continues in Boston. Emerging Treatments | Update on Hematologic Cancers examines how next-generation cellular therapies, bispecific antibodies and targeted medicines are shifting care away from chemotherapy toward immune-driven approaches, and moving the most effective ones earlier and closer to patients.
To hear where the science goes next, register now for the World Medical Innovation Forum, September 22–23 in Boston.”
Other articles about Mass General Brigham on OncoDaily.